Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)

NCT04364230 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Melanoma
Ocular Melanoma
Uveal Melanoma

Interventions

DRUG: 6MHP
DRUG: NeoAg-mBRAF
DRUG: PolyICLC
DRUG: CDX-1140

Sponsor

Craig L Slingluff, Jr

Collaborators

[object Object]